228 related articles for article (PubMed ID: 11084918)
1. [Properties of antitumor activity of vinorelbine tartrate, a new vinca alkaloid antitumor agent].
Kanazawa J; Morimoto M; Ohmori K
Nihon Yakurigaku Zasshi; 2000 Oct; 116(4):215-23. PubMed ID: 11084918
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of vinorelbine in the cancer therapy.
Galano G; Caputo M; Tecce MF; Capasso A
Curr Drug Saf; 2011 Jul; 6(3):185-93. PubMed ID: 22122393
[TBL] [Abstract][Full Text] [Related]
3. Vinorelbine: a novel vinca alkaloid.
Toso C; Lindley C
Am J Health Syst Pharm; 1995 Jun; 52(12):1287-304; quizz 1340-1. PubMed ID: 7656116
[TBL] [Abstract][Full Text] [Related]
4. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties.
Kruczynski A; Hill BT
Crit Rev Oncol Hematol; 2001 Nov; 40(2):159-73. PubMed ID: 11682323
[TBL] [Abstract][Full Text] [Related]
5. Activity of vinorelbine in gastrointestinal cancers.
Conroy T
Crit Rev Oncol Hematol; 2002 May; 42(2):173-8. PubMed ID: 12007975
[TBL] [Abstract][Full Text] [Related]
6. [Vinorelbine in the treatment of non-small-cell lung cancer and breast cancer].
Kubota K
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1301-6. PubMed ID: 10945030
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
8. Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). The Japan Vinorelbine Lung Cancer Cooperative Study Group.
Furuse K; Fukuoka M; Kuba M; Yamori S; Nakai Y; Negoro S; Katagami N; Takada Y; Kinuwaki E; Kawahara M; Kubota K; Sakuma A; Niitani H
Ann Oncol; 1996 Oct; 7(8):815-20. PubMed ID: 8922195
[TBL] [Abstract][Full Text] [Related]
9. Vinorelbine (Navelbine): a third-generation vinca alkaloid.
Budman DR
Cancer Invest; 1997; 15(5):475-90. PubMed ID: 9316630
[TBL] [Abstract][Full Text] [Related]
10. [Navelbine (vinorelbine): a review of its antitumor activity and toxicity in clinical studies].
Niitani H
Gan To Kagaku Ryoho; 1999 Sep; 26(10):1495-507. PubMed ID: 10500542
[TBL] [Abstract][Full Text] [Related]
11. Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy.
Goa KL; Faulds D
Drugs Aging; 1994 Sep; 5(3):200-34. PubMed ID: 7803948
[TBL] [Abstract][Full Text] [Related]
12. [A trial with single-agent vinorelbine in taxane-resistant non-small cell lung cancer].
Miyata J; Sano T; Bando H
Gan To Kagaku Ryoho; 2001 Feb; 28(2):239-42. PubMed ID: 11242654
[TBL] [Abstract][Full Text] [Related]
13. [Antitumor activity of navelbine (vinorelbine ditartrate), a new vinca alkaloid analog].
Ashizawa T; Miyoshi K; Asada M; Kobayashi E; Okabe M; Morimoto M; Gomi K; Hirata T
Gan To Kagaku Ryoho; 1993 Jan; 20(1):59-66. PubMed ID: 8422187
[TBL] [Abstract][Full Text] [Related]
14. [Combination chemotherapy with vinorelbine and other cytotoxic agents for advanced breast cancer patients--a protocol of vinorelbine plus AC regimens used by the Japan Vinorelbin Study Group].
Saeki T; Adachi I; Ogita M; Tabei T; Shin E; Tamura K; Takashima S
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1180-4. PubMed ID: 10945014
[TBL] [Abstract][Full Text] [Related]
15. Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.
Izumi H; Touge H; Igishi T; Makino H; Nishii-Ito S; Takata M; Nakazaki H; Ueda Y; Matsumoto S; Kodani M; Kurai J; Takeda K; Sakamoto T; Yanai M; Tanaka N; Nirodi CS; Shimizu E
Int J Oncol; 2015 Mar; 46(3):989-98. PubMed ID: 25573239
[TBL] [Abstract][Full Text] [Related]
16. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
[TBL] [Abstract][Full Text] [Related]
17. Vinca alkaloids cause aberrant ROS-mediated JNK activation, Mcl-1 downregulation, DNA damage, mitochondrial dysfunction, and apoptosis in lung adenocarcinoma cells.
Chiu WH; Luo SJ; Chen CL; Cheng JH; Hsieh CY; Wang CY; Huang WC; Su WC; Lin CF
Biochem Pharmacol; 2012 May; 83(9):1159-71. PubMed ID: 22285910
[TBL] [Abstract][Full Text] [Related]
18. Single-agent vinorelbine in the treatment of non-small cell lung cancer.
Wozniak AJ
Semin Oncol; 1999 Oct; 26(5 Suppl 16):62-6; discussion 71-2. PubMed ID: 10585010
[TBL] [Abstract][Full Text] [Related]
19. An increase in glucosylceramide synthase induces Bcl-xL-mediated cell survival in vinorelbine-resistant lung adenocarcinoma cells.
Chiu WH; Su WC; Li CL; Chen CL; Lin CF
Oncotarget; 2015 Aug; 6(24):20513-24. PubMed ID: 26001295
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin and vinorelbine in advanced and/or metastatic adenocarcinoma of the endometrium: a new highly active chemotherapeutic regimen.
Gebbia V; Testa A; Borsellino N; Ferrera P; Tirrito M; Palmeri S
Ann Oncol; 2001 Jun; 12(6):767-72. PubMed ID: 11484950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
